Dabigatran and cardiac events

In this large pooled analysis of all randomized trials of dabigatran, researchers found the drug was associated with a 33% increase in rates of cardiac events ( MI or ACS, OR=1.33, 95% CI 1.03 to 1.71) compared to control therapy (placebo, LMWH, or warfarin). As recommended by the ACC/AHA, dabigatran should only be used for FDA-labeled indications (e.g. Afib), and only for patients with poor INR control despite best attempts at good control (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment